Theseus Pharmaceuticals, Inc. (THRX) Research

Theseus Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and bringing to market targeted treatments for cancer patients. Their leading investigational compound, THE-630, is a pan-KIT inhibitor undergoing Phase I clinical trials for treating gastrointestinal stromal tumors. The company is also advancing a fourth-generation EGFR inhibitor specifically designed to combat the C797S EGFR mutation, which confers resistance to initial or later-line osimertinib therapy in individuals with non-small cell lung cancer. All their research and development efforts aim to overcome drug resistance mutations within key driver oncogenes, which are mutated genes that promote cancer. Founded in 2017, the company operates out of Cambridge, Massachusetts.

Market snapshot

Symbol
THRX
Price
$4.07
Day change
+0.12%
Market cap
$181.5M
P/E ratio
-3.32x
52-week range
2.05-12.37
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • aTyr Pharma, Inc. (ATYR)
  • CARGO Therapeutics, Inc. Common Stock (CRGX)
  • F-star Therapeutics, Inc. (FSTX)
  • LENZ Therapeutics, Inc. (LENZ)
  • LakeShore Biopharma Co., Ltd (LSB)
  • Selecta Biosciences, Inc. (SELB)
  • Spectrum Pharmaceuticals, Inc. (SPPI)
  • Alaunos Therapeutics, Inc. (TCRT)

Recent insider activity

  • Yi Kathy — D-Return (3250 shares) on 2024-02-14
  • Yi Kathy — D-Return (99634 shares) on 2024-02-14
  • Stein Steven H — D-Return (3250 shares) on 2024-02-14
  • ORBIMED ADVISORS LLC — U-Tender (650600 shares) on 2024-02-14
  • HAYDEN DONALD J JR — U-Tender (10000 shares) on 2024-02-14

Open Theseus Pharmaceuticals, Inc. (THRX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.